| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/16/2014 | WO2014011742A1 Method and composition for metabolic regulation |
| 01/16/2014 | WO2014011573A2 Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases |
| 01/16/2014 | WO2014011465A2 Aptamer-targeted antigen delivery |
| 01/16/2014 | WO2014011407A2 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| 01/16/2014 | WO2014011237A1 Methods and compositions for the treatment of lysosomal storage diseases |
| 01/16/2014 | WO2014011210A1 Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
| 01/16/2014 | WO2014011053A1 Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell |
| 01/16/2014 | WO2014011050A1 Exon replacement with stabilized artificial rnas |
| 01/16/2014 | WO2014010758A1 Anti-tumour agent, marker for tumour detection, and oral vaccine agent |
| 01/16/2014 | WO2014009567A1 Compositions and methods for duchenne muscular dystrophy gene therapy |
| 01/16/2014 | WO2013164793A3 Viral vectors for the treatment of retinal dystrophy |
| 01/16/2014 | US20140017774 Pca3, pca3 genes, and methods of use |
| 01/16/2014 | US20140017766 Targeting pseudotyped retroviral vectors |
| 01/16/2014 | US20140017300 Delivery of nucleic acid-like compounds |
| 01/16/2014 | US20140017273 Albumin-Fused Anti-Angiogenesis Peptides |
| 01/16/2014 | US20140017241 Non-natural ribonuclease conjugates as cytotoxic agents |
| 01/16/2014 | US20140017212 Methods and compositions for the treatment of lysosomal storage diseases |
| 01/16/2014 | US20140017201 Viral vectors for the treatment of retinal dystrophy |
| 01/16/2014 | CA2878171A1 Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
| 01/16/2014 | CA2876730A1 Enhancing activity of car t cells by co-introducing a bispecific antibody |
| 01/16/2014 | CA2876499A1 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| 01/16/2014 | CA2875618A1 Methods and compositions for the treatment of lysosomal storage diseases |
| 01/15/2014 | EP2684892A1 Compositions and methods for duchenne muscular dystrophy gene therapy |
| 01/15/2014 | EP2683837A2 Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker |
| 01/15/2014 | EP2683411A1 Methods of using microrna-26a to promote angiogenesis |
| 01/15/2014 | CN103509868A Application of nucleotide sequence |
| 01/15/2014 | CN103509797A Small molecule RNA, preparation method thereof and application in pharmaceuticals for transcriptional activity of specificity up-regulated genes |
| 01/15/2014 | CN103509183A Degradable gene vector based on polyethyleneimine and preparation method thereof |
| 01/15/2014 | CN103509182A Polyethyleneimine-based gene vector with high buffer capacity and preparation method thereof |
| 01/15/2014 | CN103505745A Application of micromolecule RNA used as immunosuppressor |
| 01/15/2014 | CN103505744A Gene delivery system of targeting brain capillary endothelial cell |
| 01/15/2014 | CN103505743A Cell micro-particles containing functional microRNA/siRNA and application thereof |
| 01/15/2014 | CN103505742A Difunctional 3p-siRNA inhibiting hepatitis B viruses, and application thereof |
| 01/15/2014 | CN103031334B Dual-target siRNA eukaryotic expression plasmid capable of inhibiting STAT3 and AFP gene expression, and application of expression plasmid |
| 01/15/2014 | CN103007292B MiR-3OB (Micro-Ribonucleic Acid-30b) composite for targeting microglia as well as preparation method and application of composite |
| 01/15/2014 | CN102732515B Nucleotide sequence and application thereof |
| 01/15/2014 | CN102533855B Gene-vector composition of targeted microglia as well as preparation method and application of gene-vector composition |
| 01/15/2014 | CN102516552B Degradable acid-sensitive macromolecular amphipathic cationic block copolymers and micellar particles and preparation method thereof |
| 01/15/2014 | CN102260667B Preparation of cell microparticle-siRNA composite and application thereof in treating AIDS |
| 01/15/2014 | CN102146418B Recombinant II type herpes simplex virus vector, preparation method of recombinant II type herpes simplex virus vector, recombinant virus, medicinal composition and application |
| 01/14/2014 | US8629261 Olig1 mini-promoters |
| 01/14/2014 | US8629120 Method of treatments related to the FMR1 gene |
| 01/14/2014 | US8629107 Genes and proteins associated with angiogenesis and uses thereof |
| 01/14/2014 | US8628785 Method for augmenting the immunogenicity of an antigen |
| 01/14/2014 | CA2563312C Plasmid mediated ghrh supplementation for renal failures |
| 01/14/2014 | CA2519875C Method of tumor regression with vegf inhibitors |
| 01/14/2014 | CA2504926C Compositions and methods for sirna inhibition of hif-1 alpha |
| 01/14/2014 | CA2418088C Numb protein expression inhibitors by musashi 1 |
| 01/14/2014 | CA2402530C Blocking leukocyte emigration and inflammation by interfering with cd99 |
| 01/14/2014 | CA2370252C Cancer treatment with endothelin receptor antagonists |
| 01/09/2014 | WO2014008334A1 Stable non-aggregating nucleic acid lipid particle formulations |
| 01/09/2014 | WO2014007620A2 Oligonucleotide for the treatment of muscular dystrophy patients |
| 01/09/2014 | WO2014007438A1 Aptamer for periostin and anti-cancer composition including same |
| 01/09/2014 | WO2014007402A1 Differentiation marker for and differentiation control for ocular cells |
| 01/09/2014 | WO2014007398A1 Cationic lipid |
| 01/09/2014 | WO2014006114A1 New treatment for neurodegenerative diseases |
| 01/09/2014 | WO2013151666A3 Modified polynucleotides for the production of biologics and proteins associated with human disease |
| 01/09/2014 | WO2013142153A3 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| 01/09/2014 | US20140011977 Chimeric molecules to modulate gene expression |
| 01/09/2014 | US20140010861 Modified polynucleotides for the production of proteins associated with human disease |
| 01/09/2014 | US20140010798 Albumin fusion proteins |
| 01/09/2014 | CA2877644A1 Oligonucleotide for the treatment of muscular dystrophy patients |
| 01/08/2014 | EP2682469A1 Optically controlled gene expression system |
| 01/08/2014 | EP2682466A1 siRNA conjugate and preparation method thereof |
| 01/08/2014 | EP2682459A1 Oncolytic adenovirus for target therapy of human tumor and use thereof |
| 01/08/2014 | EP2681336A2 Enhanced biodistribution of oligomers |
| 01/08/2014 | EP2681327A2 Vectors conditionally expressing protein |
| 01/08/2014 | CN103502458A Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer |
| 01/08/2014 | CN103501824A Enhanced therapeutic usage of a purine nucleoside phosphorylase or nucleoside hydrolase prodrug related applications |
| 01/08/2014 | CN103501823A Multicomponent compositions and their uses |
| 01/08/2014 | CN103501822A Treatment of spinal cord injury and traumatic brain injury using placental stem cells |
| 01/08/2014 | CN103501794A Brain-targeting functional nucleic acid and use thereof |
| 01/08/2014 | CN103497952A PTEN (phosphatase and tensin homolog) gene interference shRNA3, and recombinant adenovirus vector and construction thereof |
| 01/08/2014 | CN103497927A Recombination BCG viable bacterium strain capable of expressing and secreting staphylococcus aureus enterotoxin protein, viable bacterium vaccine and construction method and application thereof |
| 01/08/2014 | CN103497926A Recombination BCG viable bacterium strain capable of expressing and secreting human p53 protein, viable bacterium vaccine and construction method and application thereof |
| 01/08/2014 | CN103497241A Prawn anti-viral Argonaute protein, as well as encoding cDNA (complementary deoxyribonucleic acid) and application thereof |
| 01/08/2014 | CN103495182A Newcastle disease diad vaccine and preparation method thereof |
| 01/08/2014 | CN103495181A Application of miR-375 |
| 01/08/2014 | CN102908631B Function of actin 84 lysine monomethylation in cytokinesis and cell proliferation as well as application thereof to drug development |
| 01/08/2014 | CN102659980B Method for preparing double hydrophilic thermo-sensitive polymer nano micelles |
| 01/08/2014 | CN102659979B Preparation method of double-hydrophilic temperature response polymer |
| 01/08/2014 | CN102586437B Application of CCDC72 gene and expression product thereof in preparing preparation for diagnosing and treating ovarian cancer |
| 01/08/2014 | CN102321584B Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
| 01/08/2014 | CN102199608B Efficient expression of pinellia ternate agglutinin (PTA) in bombyx mori reactor |
| 01/07/2014 | US8624019 ENA nucleic acid drugs modifying splicing in mRNA precursor |
| 01/07/2014 | US8624000 Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
| 01/07/2014 | US8623837 Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| 01/07/2014 | US8623836 Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| 01/07/2014 | US8623835 Materials and methods for treatment of respiratory allergic diseases |
| 01/07/2014 | US8623831 Nuclear factor κB inducing factor |
| 01/07/2014 | US8623810 Protease for wound conditioning and skin care |
| 01/07/2014 | US8623643 Antisense oligonucleotide modulation of STAT3 expression |
| 01/07/2014 | US8623609 Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents |
| 01/07/2014 | US8623379 Compositions and methods for generating an immune response |
| 01/07/2014 | US8623350 Protease inhibitor: protease sensitivity expression system and method improving the therapeutic activity and specificity of proteins and phage and phagemids delivered by bacteria |
| 01/07/2014 | US8623349 Systems, methods and microrganisms for antibody production with type III secretion system |
| 01/07/2014 | CA2665958C High affinity binding site of hgfr and methods for identification of antagonists thereof |
| 01/07/2014 | CA2492472C Use of urease for inhibiting cancer cell growth |
| 01/07/2014 | CA2453967C Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/07/2014 | CA2427896C Carrier vectors through an epithelium with tight junctions |